AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25995057 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated multi-element psychosocial intervention (cognitive behavioral therapy, family intervention, and case management)
Number of subjects: 444
Study 25995057 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 444
Study 25995057 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated multi-element psychosocial intervention
Number of subjects: 444
Study 23877591 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic screening (n = 3272)
Number of subjects: 6861
Study 23877591 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 3589)
Number of subjects: 6861
Study 23877591 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic screening
Number of subjects: 6861
Study 23877591 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6861
Study 21755338 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian diathermy (LOD)
Number of subjects: 176
Study 21755338 — intervention group
Group type: COMPARATOR
Intervention: Continuation of clomiphene citrate (CC)
Number of subjects: 176
Study 19292807 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 0
Study 19292807 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 0
Study 19292807 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant tamoxifen therapy
Number of subjects: 0
Study 17727573 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidiuresis treatment
Number of subjects: 0
Study 15118640 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) < 5 years
Number of subjects: 69
Study 15118640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 15118640 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) > or =5 years
Number of subjects: 69
Study 11333075 — intervention group
Group type: EXPERIMENTAL
Intervention: Overheard speech (novel words used by others)
Number of subjects: 88
Study 11333075 — intervention group
Group type: COMPARATOR
Intervention: Directly addressed speech (novel words used directly to the child)
Number of subjects: 88
Study 11333075 — intervention group
Group type: EXPERIMENTAL
Intervention: Overheard speech (object labels)
Number of subjects: 88
Study 11333075 — intervention group
Group type: EXPERIMENTAL
Intervention: Overheard speech (action verbs)
Number of subjects: 88
Study 9393428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental implants not coated with hydroxyapatite
Number of subjects: 0
Study 9393428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental implants placed in the maxilla
Number of subjects: 0
Study 9393428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental implants placed in anterior regions of the jaws
Number of subjects: 0
Study 9393428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental implants in completely edentulous cases
Number of subjects: 0
Study 9393428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental implants placed in bone scored as having lower quality
Number of subjects: 0
Study 8120685 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational module including written material and a two-hour seminar
Number of subjects: 0
Study 3037676 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (ansamycin LM 427)
Number of subjects: 0
Study 29872267 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel/carboplatin
Number of subjects: 65
Study 29872267 — intervention group
Group type: COMPARATOR
Intervention: paclitaxel/carboplatin
Number of subjects: 65
Study 28572749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate extract (POMx) 1000 mg
Number of subjects: 8
Study 28572749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate extract (POMx)
Number of subjects: 8
Study 28572749 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 8
Study 26176805 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 25 mg/day for 12 weeks
Number of subjects: 26
Study 26176805 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole (AZ) 1 mg/day for 12 weeks
Number of subjects: 26
Study 26176805 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 26
Study 26176805 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole (AZ)
Number of subjects: 26
Study 23957734 — intervention group
Group type: COMPARATOR
Intervention: Active mesalazine 1.6 g/day plus Lactobacillus casei subsp. DG placebo (Group M)
Number of subjects: 210
Study 23957734 — intervention group
Group type: COMPARATOR
Intervention: Active Lactobacillus casei subsp. DG 24 billion/day plus mesalazine placebo (Group L)
Number of subjects: 210
Study 23957734 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Lactobacillus casei subsp. DG 24 billion/day plus active mesalazine (Group LM)
Number of subjects: 210
Study 23957734 — intervention group
Group type: COMPARATOR
Intervention: Lactobacillus casei subsp. DG placebo plus mesalazine placebo (Group P)
Number of subjects: 210
Study 23957734 — intervention group
Group type: COMPARATOR
Intervention: Group P (placebo)
Number of subjects: 210
Study 23957734 — intervention group
Group type: COMPARATOR
Intervention: Group L (placebo)
Number of subjects: 210
Study 22012522 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg orally once weekly for six months
Number of subjects: 73
Study 22012522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 18995174 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based home disease management program (Alere DayLink HF Monitoring System [HFMS])
Number of subjects: 315
Study 18995174 — intervention group
Group type: COMPARATOR
Intervention: Standard heart failure care (SC: enhanced patient education, education to clinicians, and follow-up)
Number of subjects: 315
Study 18995174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HFMS and SC)
Number of subjects: 315
Study 16311042 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Maximum Voluntary Contraction (MVC)
Number of subjects: 12
Study 16311042 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Maximum Voluntary Contraction (MVC)
Number of subjects: 12
Study 16311042 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Unit Action Potential Trains (MUAPTs) during 20% MVC
Number of subjects: 12
Study 12859312 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI treatment
Number of subjects: 42
Study 12859312 — intervention group
Group type: COMPARATOR
Intervention: NonACEI treatment (Control)
Number of subjects: 42
Study 10479163 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected vaginal swabs for HPV testing by hybrid capture assay
Number of subjects: 960
Study 8599790 — intervention group
Group type: EXPERIMENTAL
Intervention: Harvesting of the IMA with opening the pleura (130 patients)
Number of subjects: 280
Study 8599790 — intervention group
Group type: COMPARATOR
Intervention: Harvesting of the IMA without opening the pleura (150 patients)
Number of subjects: 280
Study 8599790 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 280
Study 1755537 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 51
Study 1755537 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 51
Study 1755537 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 51
Study 6310464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime sodium at a dose of 6 g/day
Number of subjects: 118
Study 6310464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime sodium
Number of subjects: 118
Study 6310464 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin and gentamicin
Number of subjects: 118
Study 6310464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime sodium at a dose of 3 g/day
Number of subjects: 118
Study 30793441 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve modulation (SNM) - subsensory setting
Number of subjects: 21
Study 30793441 — intervention group
Group type: COMPARATOR
Intervention: Sacral nerve modulation (SNM) - OFF setting
Number of subjects: 21
Study 31280535 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling Treatment (ST)
Number of subjects: 37
Study 31280535 — intervention group
Group type: COMPARATOR
Intervention: Conventional Treatment (CT)
Number of subjects: 37
Study 29390557 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet group (intervention)
Number of subjects: 0
Study 29390557 — intervention group
Group type: COMPARATOR
Intervention: Nonleaflet group (control)
Number of subjects: 0
Study 26035652 — intervention group
Group type: EXPERIMENTAL
Intervention: DAFOs
Number of subjects: 10
Study 26035652 — intervention group
Group type: EXPERIMENTAL
Intervention: ADR-AFOs
Number of subjects: 10
Study 26035652 — intervention group
Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 10
Study 23871569 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermal autograft
Number of subjects: 48
Study 23871569 — intervention group
Group type: COMPARATOR
Intervention: Acellular dermal matrix (ADM)
Number of subjects: 48
Study 21803872 — intervention group
Group type: EXPERIMENTAL
Intervention: American ginseng (100 mg, 200 mg, 400 mg/day)
Number of subjects: 56
Study 21803872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 19538734 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic CareLink monitor for remote transmission
Number of subjects: 200
Study 19538734 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of in-person evaluations
Number of subjects: 200
Study 16952819 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL ropivacaine 0.5%
Number of subjects: 60
Study 16952819 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL ropivacaine 0.5%
Number of subjects: 60
Study 16952819 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL ropivacaine 0.5%
Number of subjects: 60
Study 15291234 — intervention group
Group type: EXPERIMENTAL
Intervention: Order of report manipulation
Number of subjects: 14
Study 15291234 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-related brain potentials analysis
Number of subjects: 14
Study 11720748 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and cisplatin
Number of subjects: 0
Study 9475308 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels in infected children with severe PEM
Number of subjects: 27
Study 9475308 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels in non-infected children with severe PEM
Number of subjects: 27
Study 9475308 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein (CRP) levels in healthy non-infected controls
Number of subjects: 27
Study 9475308 — intervention group
Group type: EXPERIMENTAL
Intervention: C3 complement protein levels in non-infected children with severe PEM
Number of subjects: 27
Study 9475308 — intervention group
Group type: EXPERIMENTAL
Intervention: C3 complement protein levels in infected children with severe PEM
Number of subjects: 27
Study 8189743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue exposure treatment
Number of subjects: 31
Study 3235927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical adjusting
Number of subjects: 26
Study 3235927 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluteal massage
Number of subjects: 26
Study 3235927 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 26
Study 29395018 — intervention group
Group type: EXPERIMENTAL
Intervention: Video feedback
Number of subjects: 0
Study 29395018 — intervention group
Group type: COMPARATOR
Intervention: Traditional feedback
Number of subjects: 0
Study 27761966 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Task-Oriented (TO) intervention for 6 weeks, 3 hours per week
Number of subjects: 20
Study 27761966 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 24097288 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA)
Number of subjects: 166
Study 24097288 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin plus low-intensity warfarin (LDA + W)
Number of subjects: 166
Study 24097288 — intervention group
Group type: COMPARATOR
Intervention: Observational arm (LDA)
Number of subjects: 166
Study 24160231 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with daily supplementation of 10,000 IU of vitamin A, 400 mg of vitamin E, and 600 mg of vitamin C (G2)
Number of subjects: 34
Study 24160231 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (G1)
Number of subjects: 34
Study 21923449 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol ER 100 mg with paroxetine
Number of subjects: 15
Study 21923449 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol ER 200 mg with paroxetine
Number of subjects: 15
Study 21923449 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol IR (two 100 mg doses) with paroxetine
Number of subjects: 15
Study 21923449 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol IR with paroxetine
Number of subjects: 15
Study 21923449 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 15
Study 18312046 — intervention group
Group type: EXPERIMENTAL
Intervention: LETS Act! (brief behavioral therapy for depression)
Number of subjects: 44
Study 18312046 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 44
Study 12971812 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 0
Study 12971812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11079089 — intervention group
Group type: EXPERIMENTAL
Intervention: GPW mixture (gelatin, Peritrast, and water) administered over an intestinal tube
Number of subjects: 20
Study 11079089 — intervention group
Group type: COMPARATOR
Intervention: Small bowel enema
Number of subjects: 20
Study 11079089 — intervention group
Group type: COMPARATOR
Intervention: SBFT
Number of subjects: 20
Study 8837238 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg leuprolide depot intramuscularly every 28 days for 24 weeks
Number of subjects: 50
Study 8837238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1608407 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin treatment
Number of subjects: 36
Study 1608407 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 36
Study 555483 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinterpreting the pain stimuli
Number of subjects: 0
Study 555483 — intervention group
Group type: EXPERIMENTAL
Intervention: Diverting one's attention from pain
Number of subjects: 0
Study 555483 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrating on the sensation itself
Number of subjects: 0
Study 31148492 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute dietary nitrate supplementation (6.2 mmol), 2 hours prior to testing
Number of subjects: 17
Study 31148492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 28976426 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA
Number of subjects: 194
Study 28976426 — intervention group
Group type: COMPARATOR
Intervention: EACA
Number of subjects: 194
Study 26033430 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (Project SHARE) - personalized reports, educational materials, drinking diaries, in-person physician advice, telephone counseling by health educators (HEs)
Number of subjects: 1186
Study 26033430 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 1186
Study 24043751 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg
Number of subjects: 1432
Study 24043751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1432
Study 24043751 — intervention group
Group type: COMPARATOR
Intervention: Overall study population
Number of subjects: 1432
Study 21316647 — intervention group
Group type: EXPERIMENTAL
Intervention: Ineffectiveness induction (participants recalled a past experience when they felt useless or incapable)
Number of subjects: 120
Study 21316647 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 120
Study 21316647 — intervention group
Group type: EXPERIMENTAL
Intervention: Ineffectiveness induction
Number of subjects: 120
Study 20032953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereton (1000 mg)
Number of subjects: 60
Study 20032953 — intervention group
Group type: COMPARATOR
Intervention: Piracetam (2000 mg)
Number of subjects: 60
Study 16762944 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine intake of 38 mg . kg(‐1) . d(‐1)
Number of subjects: 32
Study 16762944 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine intake of 37 mg . kg(‐1) . d(‐1)
Number of subjects: 32
Study 17273582 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 31
Study 17273582 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 31
Study 14992111 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified technique for radial artery harvesting
Number of subjects: 0
Study 14992111 — intervention group
Group type: COMPARATOR
Intervention: Standard technique for radial artery harvesting
Number of subjects: 0
Study 10204971 — intervention group
Group type: EXPERIMENTAL
Intervention: General anxiety
Number of subjects: 833
Study 10204971 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer worries
Number of subjects: 833
Study 8665998 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional rapid release preparation of oxipurinol sodium
Number of subjects: 10
Study 8665998 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxipurinol as free acid
Number of subjects: 10
Study 8665998 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated microtablets of oxipurinol sodium
Number of subjects: 10
Study 8665998 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (300 mg)
Number of subjects: 10
Study 2218006 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline 150 mg bd for 2 weeks, then 300 mg bd for 3 weeks
Number of subjects: 85
Study 2218006 — intervention group
Group type: COMPARATOR
Intervention: Theophylline 150 mg bd for 2 weeks, then 300 mg bd for 3 weeks
Number of subjects: 85
Study 7446916 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane anaesthesia
Number of subjects: 100
Study 7446916 — intervention group
Group type: COMPARATOR
Intervention: Halothane anaesthesia
Number of subjects: 100
Study 29650037 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental schedule 2/1 (50 mg daily)
Number of subjects: 248
Study 29650037 — intervention group
Group type: COMPARATOR
Intervention: Standard schedule 4/2 (37.5 mg daily)
Number of subjects: 248
Study 29650037 — intervention group
Group type: EXPERIMENTAL
Intervention: Both schedules
Number of subjects: 248
Study 28829877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 160
Study 28829877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 26699730 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect Consciousness (AC) intervention
Number of subjects: 52
Study 23263000 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9851 400 mg once daily for 3 days
Number of subjects: 32
Study 23263000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 21400557 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced carbohydrate diet (n = 84)
Number of subjects: 170
Study 21400557 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced fat diet (n = 86)
Number of subjects: 170
Study 21400557 — intervention group
Group type: COMPARATOR
Intervention: Both diets (reduced carbohydrate and reduced fat)
Number of subjects: 170
Study 18190557 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG+PRP
Number of subjects: 40
Study 18190557 — intervention group
Group type: COMPARATOR
Intervention: CTG
Number of subjects: 40
Study 16137833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhaler, bupropion, or both for smoking cessation
Number of subjects: 1692
Study 12829988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (1,000-1,200 mg daily)
Number of subjects: 34
Study 12829988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 10996722 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (n=20; 1052 lymph nodes)
Number of subjects: 40
Study 10996722 — intervention group
Group type: COMPARATOR
Intervention: Surgery (n=20; 929 lymph nodes)
Number of subjects: 40
Study 8898828 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 0
Study 8898828 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 1797498 — intervention group
Group type: EXPERIMENTAL
Intervention: Human ultralente insulin before supper
Number of subjects: 20
Study 1797498 — intervention group
Group type: COMPARATOR
Intervention: NPH (isophane) before breakfast
Number of subjects: 20
Study 6617072 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg lorazepam
Number of subjects: 6
Study 6617072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30545786 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 99
Study 30545786 — intervention group
Group type: COMPARATOR
Intervention: Interscalene nerve block (ISB)
Number of subjects: 99
Study 27927601 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum)
Number of subjects: 60
Study 27927601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25641899 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience Training
Number of subjects: 1939
Study 25641899 — intervention group
Group type: COMPARATOR
Intervention: Military History
Number of subjects: 1939
Study 24347664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with a defibrillator (CRT-D)
Number of subjects: 1785
Study 24347664 — intervention group
Group type: COMPARATOR
Intervention: Defibrillator-only therapy
Number of subjects: 1785
Study 21890585 — intervention group
Group type: EXPERIMENTAL
Intervention: TPA023 (2 mg)
Number of subjects: 9